Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study

doi:10.18632/aging.102227

CNU IR > College of Smart Living > Dept. of Life and Health Science > Periodical Articles > Item 310902800/32502

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32502

Title:	Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study
Authors:	Hung, Peir-Haur Yeh, Chih-Ching Sung, Fung-Chang Hsiao, Chih-Yen Muo, Chih-Hsin Hung, Kuan-Yu Tsai, Kuen-Jer
Contributors:	Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth China Med Univ, Dept Publ Hlth China Med Univ Hosp, Management Off Hlth Data China Med Univ, Coll Med, Sch Med, Grad Inst Clin Med Sci Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Internal Med Natl Cheng Kung Univ, Coll Med, Inst Clin Med Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Ctr Clin Med
Keywords:	Alzheimer's disease erythropoietin end-stage renal disease hemodialysis
Date:	2019
Issue Date:	2020-07-29 13:47:36 (UTC+8)
Publisher:	IMPACT JOURNALS LLC
Abstract:	Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.
Relation:	Aging-Us, v.11, n.17, pp.
Appears in Collections:	[Dept. of Life and Health Science] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1188	View/Open

Loading...